DC’s Prescription Drug Excessive Pricing Act Federally Preempted
Client Alert | 1 min read | 08.03.07
In BIO et al. v. District of Columbia et al. (case no. 2006-1593, Fed. Cir. 2007), a Federal Circuit panel declares the District of Columbia’s Prescription Drug Excessive Pricing Act (“the Act”) preempted by the federal patent laws. The Act makes it unlawful for any drug manufacturer or licensee to sell or supply for sale or impose minimum resale requirements for a patented prescription drug that results in the prescription drug being sold in the District for an “excessive price”, a term not specifically defined. Instead, it provides that excessive pricing exists where the wholesale price of a patented prescription drug in the District is over 30% higher than the comparable price in any high income country in which the product is protected by patents or other exclusive marketing rights, e.g., in the United Kingdom, Germany, Canada or Australia. The Act also provides for both public and private enforcement as well as a wide array of remedies, including but not limited to, temporary, preliminary, or permanent injunctions to enjoin the sales of prescription drugs in the District at excessive prices, fines, damages, including treble damages, and attorney’s fees.
The panel notes that, while there is no express provision in the patent statute that prohibits states from regulating the price of patented goods, state law must yield to congressional enactments if it stands as an obstacle to the accomplishment and execution of the purposes and objectives of Congress. In the federal patent statute, Congress strikes a balance between rewarding innovation and providing free consumer access by placing limitations on the scope of a patentee’s exclusionary power, the duration of the patent term and the conditions for patentability. The Act attempts to shift that balance, says the panel, penalizing high prices and limiting the full exercise of the market power that derives from a patent. Thus, the District is seen as having attempted to change federal patent policy within its borders.
Insights
Client Alert | 3 min read | 10.15.25
On August 15, 2025, the Treasury Department and IRS released updated guidance concerning Beginning of Construction requirements to qualify for clean energy tax credits. This new guidance is critical for developers to consider as they rush to qualify for the tax credits before they expire entirely. The much-anticipated guidance followed the July 7, 2025 Executive Order 14315, Ending Market Distorting Subsidies for Unreliable, Foreign-Controlled Energy Sources (“July 7, 2025 Executive Order”), which signaled that the Trump Administration was planning to strictly enforce the termination of production and investment tax credits for solar and wind facilities that are set to expire under the One Big Beautiful Bill Act (OBBB Act), covered in more detail here. The new guidance comes at a time when many in the industry are struggling to keep up with the myriad ways that the new administration is working to roll back wind and solar tax credits, leaving developers to piece through the recent guidance to determine how best to structure and invest in clean energy projects given the volatile position of the current administration vis-a-vis wind and solar energy.
Client Alert | 10 min read | 10.15.25
Client Alert | 4 min read | 10.14.25
Client Alert | 35 min read | 10.13.25
Building Blocks of Design Law: CJEU rules on LEGO Group Modular Design Protection